Transcatheter closure of perimembranous ventricular septal defect with the Amplatzer® membranous VSD occluder 2: Initial world experience and one-year follow-up


  • Conflict of interest: A. Tzikas, J. Miró, and R. Ibrahim are occasional proctors for AGA-St-Jude and J. Bass is a consultant for the same company.



To describe the initial world experience and mid-term follow-up of perimembranous ventricular septal defect (pmVSD) closure with a newly designed occluder.


Transcatheter closure of pmVSDs has been associated with a substantial risk of complete heart block, prompting many centers to abandon this intervention.


A prospective multicenter cohort study was conducted on patients with pmVSD undergoing catheter closure using the Amplatzer® Membranous VSD Occluder 2 in the initial 4 pilot centers.


Nineteen patients, median age 6 years (range 1.4–62 years), were enrolled and followed for 14 ± 3 months (range 8–20 months). The median weight was 26 kg (range 9.3–96 kg) and the mean Qp/Qs ratio was 1.8 ± 0.7. The defect on left ventricular side measured 9.9 ± 3.5 mm and the orifice on right ventricular side was 8.1 ± 2.8 mm by echocardiography. Mean device size was 9.4 ± 2.4 mm (range 5–14 mm). An eccentric device was employed in 9 patients (47%) and a concentric device in 10 (53%). Overall, 18 patients (95%) had successful device implants. Procedural time was 122 ± 39 min. There were no procedural complications. Mild residual shunting was initially observed in 14 (78%) patients. At last follow-up, mild residual shunting persisted in only 3 (17%) patients. There was no significant increase in aortic or tricuspid regurgitation. No patient had any degree of AV block, although one developed a transient left anterior fascicular block. Holter evaluation, obtained in all patients, was unremarkable in all.


This early cohort experience using a novel adapted transcatheter closure device for pmVSD suggests that the procedure is feasible, safe, and effective. © 2013 Wiley Periodicals, Inc.